Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via “Antigen Capsid-Incorporation” strategy  by Gu, Linlin et al.
Virology 487 (2016) 75–84Contents lists available at ScienceDirectVirologyhttp://d
0042-68
n Corr
eases, U
AL 3529
E-mjournal homepage: www.elsevier.com/locate/yviroAdenoviral vectors elicit humoral immunity against variable loop 2
of clade C HIV-1 gp120 via “Antigen Capsid-Incorporation” strategy
Linlin Gu a, Valentina Krendelchtchikova a, Alexandre Krendelchtchikov a,
Anitra L. Farrow a, Cynthia A. Derdeyn b,c, Qiana L. Matthews a,d,n
a Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 845 19th Street South, Birmingham, AL 35294, USA
b Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30329, USA
c Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
d Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294, USAa r t i c l e i n f o
Article history:
Received 19 May 2015
Returned to author for revisions
7 October 2015
Accepted 8 October 2015
Available online 23 October 2015
Keywords:
HIV-1 vaccine
Adenoviral (Ad) vector
“Antigen Capsid-Incorporation” strategy
Variable loop2 (V2)
Humoral immunity
IgG isotypesx.doi.org/10.1016/j.virol.2015.10.010
22/& 2015 Published by Elsevier Inc.
esponding author at: Department of Medicin
niversity of Alabama at Birmingham, 845 19t
4, USA.
ail address: qlm@uab.edu (Q.L. Matthews).a b s t r a c t
Adenoviral (Ad) vectors in combination with the "Antigen Capsid-Incorporation" strategy have been
applied in developing HIV-1 vaccines, due to the vectors' abilities in incorporating and inducing
immunity of capsid-incorporated antigens. Variable loop 2 (V2)-speciﬁc antibodies were suggested in the
RV144 trial to correlate with reduced HIV-1 acquisition, which highlights the importance of developing
novel HIV-1 vaccines by targeting the V2 loop. Therefore, the V2 loop of HIV-1 has been incorporated into
the Ad capsid protein. We generated adenovirus serotype 5 (Ad5) vectors displaying variable loop 2 (V2)
of HIV-1 gp120, with the "Antigen Capsid-Incorporation" strategy. To assess the incorporation cap-
abilities on hexon hypervariable region1 (HVR1) and protein IX (pIX), 20aa or full length (43aa) of V2 and
V1V2 (67aa) were incorporated, respectively. Immunizations with the recombinant vectors signiﬁcantly
generated antibodies against both linear and discontinuous V2 epitopes. The immunizations generated
durable humoral immunity against V2. This study will lead to more stringent development of various
serotypes of adenovirus-vectored V2 vaccine candidates, based on breakthroughs regarding the
immunogenicity of V2.
& 2015 Published by Elsevier Inc.Introduction
Since the beginning of the human immunodeﬁciency virus type 1
(HIV-1) epidemic, nearly 70 million infections have occurred, and
approximately 35 million people have died of AIDS (http://www.who.
int/gho/hiv/en/). Tremendous progress has been made to combat the
HIV-1 epidemic, such as development of new drugs. However, drugs
alone have failed to successfully eradicate HIV-1 infections due to the
high genetic variation of HIV-1, multidrug resistance, limited access to
treatment due to cost of drugs and/or potential side-effects of drugs.
Developing a safe, inexpensive, and highly effective HIV-1 vaccine is a
priority and remains the unremitting focus for protection against
HIV-1 infection. Among the ﬁve HIV-1 vaccine clinical efﬁcacy trials
conducted, RV144 demonstrated the most promise with moderate
efﬁcacy at 31.2% (Rerks-Ngarm et al., 2009). Primary case-control
analyses in RV144 identiﬁed two major variables that were associated
with risk of HIV-1 infection: the binding of conformational plasmae, Division of Infectious Dis-
h Street South, Birmingham,IgG antibodies to a V1V2 loop of HIV-1 gp120 presented on scaffold
protein gp70 (gp70-V1V2) was inversely correlated with risk of HIV-1
infection, while the binding of plasma IgA antibodies to the Env
glycoprotein of HIV-1 was directly correlated with signiﬁcantly higher
level of HIV-1 infection (Haynes et al., 2012). Further correlation
analyses indicated that plasma IgG antibodies to linear epitopes in the
V2 loop also correlated with reduced risk of HIV-1 infection (Gottardo
et al., 2013). These statistical ﬁndings demonstrated the potential
importance of V2 in the immune-mediated protection against HIV-1
infection, and called for further efforts to focus on V2 vaccines.
The V2 loop is located on the tip of the trimeric Env protein
(Julien et al., 2013; Pancera et al., 2014; White et al., 2010), and
forms a triple spike with V1 loop and V3 loop (Liu et al., 2011). This
spike undergoes conformational changes to facilitate HIV-1 entry.
Upon the initial binding of gp120 trimer to CD4 presented on
susceptible cells, the V1V2 loops spatially rearrange to unmask V3
loop for the subsequent steps necessary for HIV-1 entry (Wilen
et al., 2012). The V2 sequence is highly variable across different
HIV-1 isolates. This variability contributes to viral evasion from the
host immune response. However, the immune-dominant V2 loop
has been characterized with several conserved structural elements
that contain highly antigenic epitopes. These epitopes are shared
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bodies against V2, including broadly neutralizing antibodies and
others (Gorny et al., 2012; Karasavvas et al., 2012; Mayr et al.,
2013; Nakamura et al., 2012). The above bio-characteristics of V2
have suggested that it is necessary and feasible to develop anti-
HIV-1 strategies that are cross-clade and can block the viral life
cycle at the cellular entry step.
Multiple viral vectors have been evaluated pre-clinically or
clinically to deliver HIV-1 immunogens to host immune systems,
most of which have demonstrated established antigenicity and
immunogenicity at various levels (Baden et al., 2013; Gomez-
Roman et al., 2006; Gomez et al., 2012; Gray et al., 2011; Hammer
et al., 2013; Rerks-Ngarm et al., 2009). Among these trials, human
Ad vectors with different serotypes have been employed, but
limited to the expression of HIV-1 genes that are incorporated into
early regions of the vectors. In this proof-of-principle study, by
utilizing the “Antigen Capsid-Incorporation” strategy (Gu et al.,
2013; Matthews et al., 2010) which features directly displaying
protein-of-interests on adenoviral capsid proteins, we sought to
investigate the incorporation, antigenicity and immunity of V1/V2
proteins on Ad5.Fig. 1. Generation of Ad5 vectors displaying various lengths of V1/V2 antigens.
(A) Full length (67aa) of V1V2 loop of HIV-1 clade C strain Z205F. 24aa in black
indicates the V1 loop and 43aa in red indicates the V2 loop. The black underlined
sequence indicates the 20aa-V2 epitope incorporated onto adenovirus. The green or
orange underlining indicates the most or sub immunodominant domain of Z205F
V2 loop according to previous study (Zolla-Pazner et al., 2013). Asterisks at aa134 of
V1 loop and at aa189 of V2 loop indicate the key residues required for the gen-
eration of the conformational antibody 6.4 C. (B) Utilizing the “Antigen Capsid-
Incorporation” strategy allowed successful incorporation of 20aa-V2, full length V2
or full length V1V2 onto hexon HVR1 or pIX locales to generate Ad-HVR1-20aa-V2,
Ad-HVR1-V2 or Ad-pIX-V1V2, separately. All incorporated sequences are from HIV-
1 clade C Env Z205FPL27MAR03ENV6.3, Genbank accession number GQ485419.
Table 1
Virological properties of Ad5 vectors.
Modiﬁed
vectors
Strain;
Clade
Viral particles
(VP/ml)
Infectious particles
(IP/ml)
VP/IP
Ad NA 3.1x1012 1.0x1011 31.0
Ad-HVR1-20aa-
V2
Z205F; C 1.2x1012 1.0x1010 120.0
Ad-HVR1-V2 Z205F; C 2.7x1011 4.5x108 600.0
Ad-pIX-V1V2 Z205F; C 6.2x1011 1.9x109 326.3
20aa-V2, full length of V2 and full length of V1V2 were incorporated in hexon HVR1
or pIX of Ad5, to generate recombinant viral vectors Ad-HVR1-20aa-V2, Ad-HVR1-
V2 or Ad-pIX-V1V2, respectively.
All V2 sequences of various lengths were selected from HIV-1 clade C
Z205FPL27MAR03ENV6.3.
The viral vector ﬁtness was determined by viral particles, infectious particles and
corresponding VP/IP ratio.Results
Incorporation of variable loop antigens onto Ad5 vector
In order to demonstrate the feasibility of incorporating various
HIV-1 loops onto the Ad5 capsid, the “Antigen Capsid-Incorpora-
tion” strategy was employed and two capsid proteins (hexon HVR1
and pIX) were assessed as insertion locales. One truncated V2
sequence and the full length V2 (43aa in red) and V1V2 (24 aa in
black and 43aa in red) sequences (Fig. 1A) were designed to gen-
erate three recombinant Ad5 vectors, named Ad-HVR1-20aa-V2,
Ad-HVR1-V2 and Ad-pIX-V1V2, respectively (Fig. 1B). The three
sequences incorporated into the Ad vectors were derived from
clade C HIV-1 strain 205 F (Lynch et al., 2011). Physical titers (VP/
ml) and infectious titers (IP/ml) were determined, leading to the
calculation of VP/IP ratios. A normal VP/IP ratio of unmodiﬁed Ad
ranges from 10–30 (Gu et al., 2013), and an acceptable VP/IP
ratio for modiﬁed vectors is below or around 1000. We observed
increased but normal VP/IP ratios for Ad-HVR1-20aa-V2 and Ad-
HVR1-V2 at 120.0 and 600.0, respectively, when compared to the
Ad vector (ratio of 31.0) (Table 1). These ratios indicated that the
two modiﬁcations on HVR1 had minimal effects on the ﬁtness of
the Ad vectors, and also suggested that longer foreign sequence
insertions into the HVR1 would further decrease stability. We
observed the VP/IP ratio of Ad-pIX-V1V2 at 326.3 (Table 1), indi-
cating achievement of a stable vector after the long sequence
incorporation into the pIX locale.
Variable loop antigens are exposed on Ad5 surface and are antigenic
Native western-blot or whole virus enzyme-linked immuno-
sorbent assay (ELISA) can detect antigens without denaturing their
spatial structure. By virtue of this property, we sought to study the
exposure and antigenicity of the variable loop antigens on the
rescued recombinant vectors. We determined whether exposure of
the V1/V2 insertions on the vector capsid surface was similar to
the native conformation of the corresponding antigens. A con-
formational human monoclonal antibody (hMAb) 6.4 C derived
from subject Z205F (Lynch et al., 2011) was applied for both
immunological methods. Native western blot analyses illustrated
that all three capsid-modiﬁed vectors Ad-pIX-V1V2, Ad-HVR1-V2
and Ad-HVR1-20aa-V2 retained speciﬁc binding to 6.4 C, when
compared to the non-incorporated vector Ad (Fig. 2A). In thewhole virus ELISA analyses, when compared to Ad, both Ad-HVR1-
V2 and Ad-HVR1-20aa-V2 bound signiﬁcantly to 6.4 C, as po0.01
(Fig. 2B). Ad-pIX-V1V2 also bound signiﬁcantly to the antibody,
when compared to Ad, as po0.05 (Fig. 2B). Taken together, the
immunologic assays demonstrated that Ad-HVR1-20aa-V2, Ad-
HVR1-V2 and Ad-pIX-V1V2 correctly present the variable loop
antigens on vector capsid surface.
Vector immunizations induce speciﬁc antibodies against linear V2
epitopes
The “prime-boost” regimenwas employed by immunizing mice
with Ad, Ad-HVR1-20aa-V2, Ad-HVR1-V2 and Ad-pIX-V1V2. Ad
was used as a negative control in order to highlight the potential
immune responses triggered by V2. The two-week intervals
between injections or between injection and bleeding (Fig. 3A)
1  2  3 4
Fig. 2. Evaluation of exposure and antigenicity of V2 antigens on recombinant Ad5
vectors. pIX has approximately one third of the molecular copies of hexon. In order
to analyze the V2 antigenicity with equal amount of V2 copies, three times higher
dosage of Ad-pIX-V1V2 was needed. (A) Native western-blot analysis was con-
ducted. Ad (lane 1,7109 VP), Ad-pIX-V1V2 (lane 2,2.11010 VP), Ad-HVR1-V2
(lane 3,7109 VP) and Ad-HVR1-20 aa -V2 (lane 4,7109 VP) were resolved on
SDS-PAGE and transferred onto PVDF membrane. The membrane was blotted with
HIV-1 205 F strain-derived hMAb 6.4 C. (B) Whole virus ELISAwas employed for the
evaluation. Ad (6109 VP/well), Ad-pIX-V1V2 (6109 VP/well), Ad-HVR1-20aa-V2
(2109 VP/well) and Ad-HVR1-V2 (2109 VP/well) were immobilized in ELISA
plates. hMAb 6.4 C was applied at 1:1000 to the coated vectors, followed by
incubation with goat anti-human IgG-HRP secondary antibody at 1:2000. The
values were expressed as the mean7standard deviation, representing three
independent replicates.
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humoral immune responses (Gu et al., 2013; Matthews et al.,
2010). C57BL/6 mice sera from Ad-HVR1-20aa-V2 immunizations
were immunologically assessed in sera-based ELISA with coating
of the linear 20aa-V2 peptide DIVPLKPNDSNSREYILINC. The data
showed increasing binding of 20aa-V2 speciﬁc sera to the peptide,
when compared to Ad sera, and the binding differences reached
signiﬁcance in both boost and reboost sera, as po0.01 and
po0.05, respectively (Fig. 3B). Isotype ELISA showed that either
IgG2b (boost) or IgG2a (reboost) were identiﬁed as dominant in
the 20aa-V2 speciﬁc sera, compared to the sera from Ad immu-
nizations, as po0.05 (Fig. 3C). We tried but failed to detect the
20aa-V2 speciﬁc immunity in the mice model of Balb/c elicited by
Ad-HVR1-20aa-V2 (Data not shown). Balb/c mice sera from Ad-
HVR1-V2 immunizations were assessed in sera-based ELISA with
coating of the linear V2 peptide EYALFYRPDIVPLKPND. Results
showed that sera from the immunization group Ad-HVR1-V2, at all
three time points (prime, boost and reboost) bound signiﬁcantly to
the linear V2 peptide, when compared to the sera from Ad
immunization group, as po0.01 (prime) and po0.001 (boost and
reboost) (Fig. 4A). The total IgGs speciﬁc for linear V2 epitopes
were quantitated between 60 μg/ml and 110 μg/ml, as post
immunization time increased. Isotype ELISA with the linear V2
peptide illustrated that all IgG isotypes (IgG1, IgG2a, IgG2b and
IgG3) against linear V2 epitopes were signiﬁcantly triggered at the
boost time point by the administration of Ad-HVR1-V2, as po0.05
(IgG1and IgG2b) and po0.001 (IgG2a and IgG3). The V2-speciﬁc
IgG1 and IgG2b isotypes were further elicited at the reboost time
point, as po0.001 (Fig. 4B). Ad-pIX-V1V2 was also investigated for
its ability to trigger V2-speciﬁc humoral immunity using ELISA
plates coated with the same linear V2 peptide. The data indicatedthat there was not a signiﬁcant elicitation of total IgGs against
linear V2 epitopes (about 20 μg/ml) at the prime time point, as
p40.05. However, V2-speciﬁc total IgGs increased to about 80 μg/
ml at reboost, and was signiﬁcant at both boost and reboost, as
po0.05 (boost) and po0.01 (reboost) (Fig. 4C). In Fig. 4D, isotype
ELISA with the identical coating peptide showed that all IgG iso-
types against linear V2 epitopes except IgG2b were signiﬁcantly
triggered at boost, as po0.05 (IgG1, IgG2a and IgG3). The sig-
niﬁcance was further enhanced for IgG2a at reboost, as po0.001.
Moreover, the binding of V2-speciﬁc IgG2b to the coated peptide
also achieved signiﬁcance, as po0.05.
Vector immunizations induce speciﬁc antibodies against dis-
continuous V2 epitopes
Since humoral immune responses to the linear epitopes in V2
were successfully demonstrated in the three recombinant Ad
vectors carrying different lengths of V1/V2 sequences on different
capsid protein locales, we sought to investigate whether these
vectors could also generate humoral immune responses against
the discontinuous epitopes in V2. There have been a few V2-
speciﬁc conformational antibodies that have been isolated from
HIV-1 infected subjects and well characterized (Mayr et al., 2013).
In this study, a cyclic V2 peptide CEYALFYRPDIVPLKPNDC was
synthesized and used for the assessment of both Ad-HVR1-V2 and
Ad-pIX-V1V2. Conformation restricted cyclic peptides are normally
designed to mimic the native secondary structure of antigens, thus
detecting conformational antibodies (Perez et al., 2006). Similar to
the total IgGs generated against linear V2 epitopes in Fig. 4A, the
conformational total IgGs against V2 were signiﬁcantly triggered
as early as the prime time point (po0.01) and were enhanced at
both boost (po0.001) and reboost time points (po0.001)
(Fig. 5A). The V2-speciﬁc conformational IgG isotypes were also
similarly elicited, with IgG1, IgG2a, IgG2b and IgG3 remaining
signiﬁcant regarding the binding to the cyclic peptide (Fig. 5B). The
assessment of Ad-pIX-V1V2 was also similar to Fig. 4C, in that
conformational total IgGs against V2 were signiﬁcantly elicited at
both boost and reboost, but not the prime time point (Fig. 5C). The
V2-speciﬁc conformational IgG isotypes were signiﬁcantly gener-
ated, including IgG1, IgG2a, IgG2b and IgG3 (Fig. 5D).
Vector immunizations induce durable V2-speciﬁc humoral immunity,
but not V2-speciﬁc IgG3
To investigate if the V2 vectors could generate durable immune
responses speciﬁc to the V2 loop, Ad-pIX-V1V2 was selected for
this evaluation. Antibodies against both linear and discontinuous
V2 epitopes were measured at different time points post reboost
by sera-based total IgG ELISAs. In an ELISA with the linear V2
peptide EYALFYRPDIVPLKPND, antibodies speciﬁc to the linear V2
epitopes from all ﬁve time points post reboost (month: 0.5, 1, 2,
3 and 4) were around 60 mg/ml, with a very slight decrease over
time. The anti-V2 antibodies from all time points bound sig-
niﬁcantly to the linear peptide, as compared to Ad (Fig. 6A). Very
similar results were obtained in ELISA with the cyclic V2 peptide
CEYALFYRPDIVPLKPNDC (Fig. 6B). Overall, the data suggests that
Ad-pIX-V1V2 induced durable humoral immunity against V2.
Recent research reported that the IgG3 speciﬁc to V2 correlates
with lower HIV-1 infection risk, but that IgG3 declines with a half-
life at 8.4 weeks (Yates et al., 2014). In this regard, we investigated
the half-life of V2-speciﬁc IgG3 generated against Ad-pIX-V1V2.
Sera-based IgG isotype ELISA with either linear V2 peptide
(Fig. 6C) or cyclic V2 peptide (Fig. 6D), both showed that there is
signiﬁcant detection of V2 IgG3 level at 0.5 and 1 month post
reboost time points, but this diminished at 2 months post reboost,
indicating a shorter half-life in the mice model.
0Week 2 4 6
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2nd Bleed & 
Reboost 3rd Bleed
Fig. 3. Schematic of homologous immunization regimen and V2-speciﬁc humoral immunity elicited by recombinant Ad vectors. (A) Balb/c mice or C57BL/6 mice were
injected with Ad-HVR1-20aa-V2 (Fig. 3), Ad-HVR1-V2 (Figs. 4, 5) or Ad-pIX-V1V2 (Figs. 4, 5), respectively. Ad was used as negative control to highlight the V2-speciﬁc
immunogenicity of each recombinant vector. The solid lines with arrow denote the time of prime, boost and reboost, the dotted lines with arrow denote the time of bleeding
post immunization. (B) C57BL/6 mice sera were collected from immunizations with Ad-HVR1-20aa-V2. Sera were evaluated for anti-V2 IgGs at post prime, boost, and reboost
time points. In the sera-based total IgG ELISA, the linear 20aa-V2 peptide was coated to titrate the concentrations of V2-speciﬁc total IgGs. (C) V2-speciﬁc IgG isotype analysis
was performed via ELISA. The 20aa-V2 peptide was coated on ELISA plates, followed by sera from boost and reboost time points. Goat anti-mouse isotypes, IgG1, IgG2a, IgG2b
and IgG3 were incubated, followed by incubation with HRP-conjugated donkey anti-goat antibody. All data were expressed as the mean7standard deviation, from four
independent replicates.
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Since the mice sera immunized with the V2 vectors recognize
the V2 peptides, it is meaningful to investigate whether the sera
also recognize native HIV-1 Env protein. Immunological ﬂuores-
cence assay (IFA) was utilized for this investigation. In this assay,
the positive control hmAb 6.4 C bound speciﬁcally and robustly to
the HIV-1 Env protein (Z205FPL27MAR03ENV6.3), as indicated by
the intensity of the green ﬂuorescence (Fig. 7A). Reboost sera from
mice immunized with Ad-HVR1-20aa-V2 showed a similar level of
basal binding background to the reboost sera from Ad, indicating
the inability of Ad-HVR1-20aa-V2 to elicit antibodies that can
recognize the Z205F Env protein (Fig. 7B). However, sera immu-
nized with Ad-HVR1-V2 showed greater binding, as substantial
green ﬂuorescence was present at the boost time point, and was
further enhanced at the reboost time point (Fig. 7C). This implied
that Ad-HVR1-V2 immunization elicited antibodies that can
recognize the Z205F Env protein at boost, and generated more
antibodies at reboost that fundamentally increased the speciﬁc
recognition. Ad-pIX-V1V2 also generated antibodies that speciﬁ-
cally recognize the Z205F Env protein, as demonstrated by green
ﬂuorescence brightness at reboost (Fig. 7D).Discussion
Over three decades, there has been a continuous effort to develop
cell-mediated or antibody-producing HIV-1 vaccines. However, allclinical trials thus far have failed in achieving efﬁcacy of protection
except the RV144 trial (Rerks-Ngarm et al., 2009), although most
preclinical vaccine trials have demonstrated antigenicity, immuno-
genicity and even various protections in animal models (Barouch et
al., 2012; Gomez-Roman et al., 2006; Patterson et al., 2004; Ratto-Kim
et al., 2012). RV144 and other clinical trials gave the vaccine ﬁeld a
glimmer of promise but also faced problems, such as the lack of
potent neutralizing antibodies against HIV-1. Although breakthroughs
like the development of artiﬁcial Env constructs that mimic the native
Env trimeric structure have been achieved, developing additional
vaccination strategies against HIV-1 infection is warranted. The V1/V2
domain of HIV-1 gp120 is one hotspot that has attracted increasing
attention to develop novel vaccine strategies, because the RV144 trial
statistically illustrated the inverse correlation of V1/V2 binding anti-
bodies with HIV-1 acquisition (Haynes et al., 2012). V1/V2 is also
attractive as a vaccine antigen because it is involved in mediating HIV-
1 entry into host cells (Wilen et al., 2012). The above illustrations
support the concept of generating V1/V2-based HIV-1 vaccines. This
study as a proof-of-concept illustrated the technical achievement of
generating Ad5 vectored V1/V2 vaccine candidates.
Ad vectors have accounted for 22.8% of gene-therapy clinical
trials by the end of 2014 (http://www.wiley.com//legacy/wileychi/
genmed/clinical/). Among the Ad vectors, Ad5 as a vaccine vector
has been intensively applied in many preclinical and clinical trials,
with proven antigenicity and immunogenicity for different
pathogens, including HIV-1 (Gomez-Roman et al., 2006; Gray
et al., 2011; Peng et al., 2005), and even protective efﬁcacy (Pandey
et al., 2012). The utility of Ad5 is the advantage that the vector can
Fig. 4. V2-speciﬁc non-conformational IgGs elicited by Ad-HVR1-V2 or Ad-pIX-V1V2. (A) Balb/c mice sera were collected from immunizations with Ad-HVR1-V2. In the sera-
based total IgG ELISA, linear V2 peptide was coated to titrate the V2-speciﬁc total IgGs (non-conformational) in sera collected from post prime, boost and reboost time points.
(B) Corresponding to the total IgG ELISA, linear V2 peptide was coated in the sera-based IgG isotype ELISA. Goat anti-mouse isotypes, IgG1, IgG2a, IgG2b and IgG3 were then
applied, followed by incubation with HRP-conjugated donkey anti-goat antibody. (C) Similarly, Balb/c mice sera were collected from immunizations with Ad-pIX-V1V2.
Linear V2 peptide was coated in the sera-based total IgG ELISA to titrate the V2-speciﬁc total IgGs (non-conformational) in sera collected from post prime, boost and reboost
time points. (D) Linear V2 peptide was coated in the sera-based IgG isotype ELISA. Goat anti-mouse isotypes, IgG1, IgG2a, IgG2b and IgG3 were then applied, followed by
incubation with HRP-conjugated donkey anti-goat antibody. All data were expressed as the mean7standard deviation, from four independent replicates.
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sequences for traditional transgene purposes (Gomez-Roman et
al., 2006; Lubeck et al., 1997), but also by incorporating foreign
antigens onto the capsid proteins (hexon, pIX, ﬁber) of the vector
via the “Antigen Capsid-Incorporation” strategy. However, a major
problem associated with Ad5 as a vaccine vector is the wide
existence of pre-immunity to Ad5 in 50–90% of normal adults,
which can potentially hamper the traditional transgene efﬁcacy of
Ad5 (Zaiss et al., 2009). Strategies have been developed to over-
come Ad5 pre-immunity, such as increasing Ad5 vectored vaccine
immunization dosages or changing immunization routes (Pandey
et al., 2012), using less prevalence serotypes for vaccine vectors
(Abbink et al., 2007), and generating Ad5 vectored vaccines via the
“Antigen Capsid-Incorporation” strategy (Shiratsuchi et al., 2010).
Pre-existing Ad5 seropositivity has been associated with HIV-1
acquisition in the STEP trial (Buchbinder et al., 2008), but not other
non-Ad HIV-1 vaccine efﬁcacy trials (Stephenson et al., 2012).
Nevertheless in this study, the major rationale was to use Ad5 to
generate V1/V2 vaccine candidates via the “Antigen Capsid-
Incorporation” strategy and conﬁrm the V2-speciﬁc antigenicity/
immunogenicity on Ad5.We previously generated various Ad5 multivalent HIV-1 vac-
cine vectors (Gu et al., 2013) and attempted to expand on this
strategy in the context of antigen capsid-incorporation in combi-
nation with V1/V2 presentation. With this strategy, we chose the
hexon HVR1 and pIX locales for incorporating V1/V2 sequences.
Our results demonstrate that we successfully incorporated differ-
ent lengths of V2 sequences onto HVR1 and their corresponding
VP/IP ratios indicated that these recombinant vectors Ad-HVR1-
20aa-V2, Ad-HVR1-V2 were stable (Fig. 1B, Table 1). We also suc-
ceeded in incorporating full length V1V2 (67aa) onto pIX to gen-
erate Ad-pIX-V1V2, indicating the high plasticity on pIX (Fig. 1B).
The corresponding VP/IP ratio also demonstrated stability of the
chimeric vector (Table 1). This incorporation strategy also
demonstrated exposure and antigenicity of V2 on Ad5 (Figs. 2A,
2B), suggesting that these chimeric Ad5 vectors can also be used to
evaluate V2 immunogenicity.
The primary reason for evaluating both mouse strains (C57BL/6
and Balb/c) initially in this study is to demonstrate that V2-speciﬁc
responses can be generated in both mouse models, which provides a
level of variability that might be similar to immune responses seen in
two individuals. Homologous repeat immunizations with each vector,
Ad-HVR1-20aa-V2, Ad-HVR1-V2 or Ad-pIX-V1V2, demonstrated
Fig. 5. V2-speciﬁc conformational IgGs elicited by Ad-HVR1-V2 or Ad-pIX-V1V2. (A) Balb/c mice sera were collected from immunizations with Ad-HVR1-V2. In the sera-
based total IgG ELISA, cyclic V2 peptide was immobilized in the ELISA plates to titrate the V2-speciﬁc total IgGs (conformational) in sera collected from post prime, boost and
reboost time points. (B) Corresponding to the total IgG ELISA, cyclic V2 peptide was immobilized in the ELISA plates in the sera-based IgG isotype ELISA. Goat anti-mouse
isotypes, IgG1, IgG2a, IgG2b and IgG3 were then applied, followed by incubation with HRP-conjugated donkey anti-goat antibody. (C) Similarly, Balb/c mice sera were
collected from immunizations with Ad-pIX-V1V2. Cyclic V2 peptide was immobilized in the ELISA plates in the sera-based total IgG ELISA to titrate the V2-speciﬁc total IgGs
(conformational) in sera collected from post prime, boost and reboost time points. (D) Cyclic V2 peptide was immobilized in the ELISA plates in the sera-based IgG isotype
ELISA. Goat anti-mouse isotypes, IgG1, IgG2a, IgG2b and IgG3 were then applied, followed by incubation with HRP-conjugated donkey anti-goat antibody. All data were
expressed as the mean7standard deviation, from four independent replicates.
L. Gu et al. / Virology 487 (2016) 75–8480signiﬁcant induction of antibodies speciﬁc to the V2 peptides when
compared to unmodiﬁed Ad immunizations. Of these, the Ad-HVR1-
20 aa-V2 vector induced comparatively low binding activity to the
linear 20aa-V2 peptide (Fig. 3B), while Ad-pIX-V1V2 induced com-
paratively high binding activity to both the linear and cyclic V2
peptides (Figs. 4C, 5C) and Ad-HVR1-V2 induced the highest response
to the both V2 peptides (Figs. 4A, 5A). The various immune response
levels among these three vectors could be explained by the incor-
poration of different regions of V1V2, consistent with ﬁndings from
the RV144 trial. The hotspot analyses in this trial found that the most
immunodominant domain (15aa peptide) of clade C V2 is located in
the crown/middle region of the V2 loop (Zolla-Pazner et al., 2013). In
the V2 sequence of Z205F strain, the most immunodominant domain
is “TEIRDKNRKEYALFY” as underlined in green, and the sub-
immunodominant domain is “RDKNRKEYALFYRPD” as underlined in
orange (Fig. 1A). The 20 aa-V2 clade C sequence (underlined in black
in Fig. 1A) in Ad-HVR1-20aa-V2 is located on the carboxyl terminus of
the V2 loop, which is poorly immunogenic. Both the V2 sequence in
Ad-HVR1-V2 and the V1V2 sequence in Ad-pIX-V1V2 contain the
immunodominant domain, which may have contributed to the high
level of V2-speciﬁc immune responses generated by both viral vec-
tors. The V2-speciﬁc antibodies from Ad-HVR1-V2 immunizations
were generated at a higher magnitude at every time point as com-
pared to the antibodies generated from Ad-pIX-V1V2 immunizations(Fig. 4A and C, 5A and C). This difference could be in part due to the
fact that pIX has only one third of the molecular copies of hexon on
each adenoviral virion. The varying immune response levels to V2
peptides among the three viral vectors were further conﬁrmed by an
immunoﬂuorescence assay, which showed that reboost sera from Ad-
HVR1-20aa-V2 immunized mice failed to bind the HIV-1 Z205F Env
protein (Fig. 7B), whereas reboost sera from Ad-pIX-V1V2 immuni-
zations did bind to this protein at a moderate level (Fig. 7D). More-
over, boost sera from Ad-HVR1-V2 immunizations showed low
binding that was enhanced by the reboost sera (Fig. 7C). The lack of
binding to the Z205F Env by sera from Ad-HVR1-20aa-V2 immunized
mice could be explained by (1) selection of mouse strain for immu-
nization (2) poor immunogenicity of the 20aa-V2; (3) the fact that
both key residues, asparagine at aa134 of V1 loop and arginine at aa189
of V2 loop (indicated with asterisks in Fig. 1A), are required for the
generation of V2 conformational antibodies, similar to 6.4 C (Lynch
et al., 2011). The 20aa-V2 only contains arginine at aa189; (4) the 20aa-
V2 might not be accessible on the Z205F Env trimer, which needs
crystal structure analysis in the future. The detection of sera binding
to the Z205F Env protein from Ad-HVR1-V2 immunizations was prior
to the detection in Ad-pIX-V1V2, which is consistent with the results
of sera binding to V2 peptides.
As stated elsewhere, the antibodies speciﬁc against both linear
and discontinuous V2 epitopes correlated with reduced risk of
Fig. 6. Vector immunizations induced durable total V2-speciﬁc humoral immunity, but not V2-speciﬁc IgG3. In the sera-based total IgG ELISA, linear V2 peptide (A) or cyclic
V2 peptide (B) was immobilized in the ELISA plates to titrate the V2-speciﬁc total IgGs in sera collected from post reboost time points (0.5, 1, 2, 3 or 4 months). In the sera-
based IgG3 ELISA, linear V2 peptide (C) or cyclic V2 peptide (D) was bound to ELISA plates. Sera from post reboost time points (0.5, 1, 2, 3 or 4 months) were bound to the
plates. Goat anti-mouse isotypes, IgG3, was then applied, followed by incubation with HRP-conjugated donkey anti-goat antibody. All data were expressed as the
mean7standard deviation, from four independent replicates.
L. Gu et al. / Virology 487 (2016) 75–84 81HIV-1 infection in the RV144 trial (Gottardo et al., 2013; Haynes
qet al., 2012). In our study, both Ad-HVR1-V2 and Ad-pIX-V1V2
elicited robust levels of anti-V2 antibodies targeting both linear V2
epitopes (Fig. 4A and C) and discontinuous V2 epitopes (Fig. 5A
and C), which is informative. To our knowledge, this is the ﬁrst
time this result has been shown in the context of V2 in combi-
nation with the “Antigen Capsid-Incorporation” strategy on Ad
vectors. Ideal vaccines should provide lasting and effective
immune protection. Our data demonstrated that the total IgGs,
speciﬁc to either linear (Fig. 6A) or discontinuous (Fig. 6B) V2
epitopes, were relatively stable for four months post reboost. This
ﬁnding implied that Ad vectors displaying V2 loops could poten-
tially induce durable humoral immunity speciﬁc to V2. Since the
V2-speciﬁc IgG3 isotype in the RV144 trial correlated with reduced
HIV-1 acquisition, but possessed a short half-life (Yates et al.,
2014), we investigated the V2-speciﬁc IgG3 duration in the mouse
model, using Ad-pIX-V1V2. The results demonstrated that IgG3
was signiﬁcantly induced at boost, and effectively maintained until
two months post reboost (Figs. 4D, 5D, 6C and D). This ﬁnding was
consistent with the result in the RV144 trial. Thus, developing the
mechanisms to increase IgG3 half-life might improve the HIV-1
vaccine efﬁcacy.Conclusion
Overall, this study is the ﬁrst to demonstrate the utility of HIV-
1 clade C V2 incorporation with the “Antigen Capsid-Incorpora-
tion” strategy. This study demonstrates V2 exposure, antigenicity,
and durable antibody responses generated in mice using two
distinct Ad5 capsid locales. As a proof-of-principle, this studyforms a foundation for more stringent development of V2 vaccine
candidates in combination with rare serotype adenoviral vectors
and the “Antigen Capsid-Incorporation” strategy.Materials and methods
Construction of recombinant Ad5 vectors
To construct two versions of Ad5 vectors displaying different
sizes of V2 of HIV-1 gp120 onto the hexon HVR1 locale of the
vector capsid, two DNA fragments were synthesized and sub-
cloned into HVR1 (a locale replaced from amino acids 139 to 144)
of shuttle plasmid H5/pH5S (Wu et al., 2005). The two fragments
are 20aa-V2 (DIVPLKPNDSNSREYILINC) and full length of V2
(CSFNATTEIRDKNRKEYALFYRPDIVPLKPNDSNSREYILINC), respec-
tively. The resulting plasmids HVR1-20aa-V2/pH5S and HVR1-V2/
pH5S were digested with EcoRI and PmeI. These resulting frag-
ments containing the homologous recombination regions and the
hexon genes were recombined through homologous recombina-
tion with a SwaI-digested Ad5 backbone lacking the hexon gene,
pAd5/ΔH5 (Wu et al., 2002). The recombination was performed
in Escherichia coli BJ5183 (Stratagene, CA), leading to the identi-
ﬁcation of positive vector clones, respectively. To construct
Ad-pIX-V1V2, full length of V1V2 sequence (CSNYNNCNDTYS-
TANCTSGGEIKNCSFNATTEIRDKNRKEYALFYRPDIVPLKPNDSNSREYI-
LINC) was subcloned into the pIX shuttle vector to generate
pIX-shuttle-V1V2. The resulting plasmid was then digested with
PmeI, the digested fragment containing the homologous recom-
bination regions and the pIX gene was recombined through
homologous recombination with an Ad5 backbone lacking the pIX
Reboost sera
Ad Ad-HVR1-20aa-V2
hMAb 6.4C
Reboost sera
Ad Ad-HVR1-V2
Boost sera
Reboost sera
Ad Ad-pIX-V1V2
Boost sera
Fig. 7. V2-speciﬁc mice sera bind to HIV-1 Z205F Env. Immunoﬂuorescence assay
was employed to evaluate whether sera from V2 immunizations could bind to HIV-
1 Z205F Env. (A) The positive control hMAb 6.4 C was applied to cells expressing
HIV Env. (B) Reboost sera from Ad or Ad-HVR1-20aa-V2 immunized mice were
applied to cells expressing HIV-1 Env. (C) Boost and reboost sera from Ad or Ad-
HVR1-V2 immunized mice were applied to cells expressing HIV-1 Env. (D) Boost
and reboost sera from Ad or Ad-pIX-V1V2 immunized mice were applied to cells
expressing HIV-1 Env.
L. Gu et al. / Virology 487 (2016) 75–8482gene. The recombination was performed in Escherichia coli BJ5183
(Stratagene, CA), leading to the identiﬁcation of positive vector
clones.
Rescue, puriﬁcation and titration of recombinant Ad5 vectors
To rescue vectors, the recombinant adenoviral genomes were
digested with PacI, and transfected with PolyJet™ in vitro DNA
transfection reagent (SignaGen Laboratories, MD). Transfections
were performed in Ad5-E1-expressing HEK293 cells. Multi-steplarge-scale propagations of recombinant Ad5 vectors were per-
formed after the vectors were rescued. To purify the rescued
vectors, two-step cesium chloride ultracentrifugation was
employed, followed by dialysis against 1x PBS containing 10%
glycerol. To titrate the puriﬁed vectors, physical titers, expressed as
viral particles (VPs) per ml were measured using absorbance at
260 nm. The infectious particles (IPs) per ml were determined by
TCID50 assay.
Native western blot
To analyze both the exposure and antigenicity of V2 on viral
vectors, vectors (7109 VP for Ad, Ad-HVR1-20aa-V2 and Ad-
HVR1-V2, and 2.11010 VP for Ad-pIX-V1V2) were mixed with 4x
native loading buffer without boiling, and resolved on native PAGE
gels, followed by transfer and blocking on PVDF membrane. Blot-
ting was performed with HIV-1 205 F strain-derived hMAb 6.4 C
(1:1,000), and with goat anti-human IgG-HRP secondary antibody
(1:2000; Southern biotech, Birmingham, AL). The proteins were
detected by using 3’3’-diaminobenzidine tablets (Sigma-Aldrich,
MO) (Gu et al., 2013).
Whole virus ELISA
The whole virus ELISAs were performed as described elsewhere
(Gu et al., 2013), in order to investigate both the exposure and
antigenicity of V2 on surface of capsid. Brieﬂy, different amounts
of vectors (2109 VP/well for Ad-HVR1-20aa-V2 and Ad-HVR1-
V2, and 6109 VP/well for Ad and Ad-pIX-V1V2) were immobi-
lized and blocked. The immobilized vectors were incubated with
hMAb 6.4 C (1:1,000), followed by incubation with goat anti-
human IgG-HRP secondary antibody (1:2000; Southern biotech,
Birmingham, AL). ELISAs were developed with the SIGMAFAST
OPD peroxidase substrate (Sigma-Aldrich, MO) and measured at
OD 450 nm.
Sera-based total IgG ELISA and IgG isotype ELISA
Sera-based total IgG ELISA was performed to determine the V2-
speciﬁc total IgG antibody binding responses in the mice sera. In
brief, V2-derived linear or cyclic peptides were immobilized on
ELISA plates at 10 μM. Sera were sequentially diluted and incu-
bated for 2 h, followed by a 2 h incubation with goat anti-mouse
IgG-HRP secondary antibody. ELISA analyses were measured as
described above.
Sera-based IgG isotype ELISA was performed to determine the
V2-speciﬁc IgG isotype distributions in the humoral immune
responses. Brieﬂy, V2-derived linear or cyclic peptides were
immobilized at 10 μM. Sera were sequentially diluted, added to
the plates, and incubated for 2 h. Then the plates were incubated
with goat anti-mouse isotypes, IgG1, IgG2a, IgG2b and IgG3
(1:1,000; Sigma-Aldrich, MO), followed by incubation with HRP-
conjugated donkey anti-goat antibody (1:5,000). Then ELISAs were
measured as above.
Mice immunization
Mice immunizations with vectors (Ad, Ad-HVR1-20aa-V2 and
Ad-pIX-V1V2) were performed to determine the V2-speciﬁc
immunogenicity. Female Balb/c or C57BL/6 mice (6–8 weeks) in
groups of eight were intramuscularly immunized with the corre-
sponding vector (11010 VP/mouse) at each time-point, with
two-week intervals among prime, boost and reboost, or between
injection and bleeding. The University of Alabama at Birmingham
Institutional Animal Use and Care Committee approved the use of
L. Gu et al. / Virology 487 (2016) 75–84 83mice as described herein under the approved protocol number
101109272.
Immunoﬂuorescence assay (IFA)
HEK293 cells were seeded in a 96-well plate and cultured
overnight to achieve a monolayer density at 80%. Plasmid
pcDNA3.1-Env (Rong et al., 2009), was designed to express the Env
protein cloned from a clade C HIV-1 infected subject Z205F
(Z205FPL27MAR03ENV6.3, Genbank accession number GQ485419)
and was transfected into the HEK293 cells with PolyJet™ in vitro
DNA transfection reagent. Transfection was carried out according
to the manufacturer’s manual. At 24 h post transfection, cells were
rinsed once in PBS, ﬁxed with 100 ml/well of cold ﬁxation solution
(Acetone: Ethanol [3:2]) for 5 min at room temperature, and air-
dried at room temperature. Fixed cells were then rinsed in PBS,
and incubated with mice sera (1:50) from prime, boost and
reboost, or hMAb 6.4 C (1:500) at room temperature for 2 h. For
the secondary antibody, rabbit anti-mouse IgG-FITC (1:100; Bio-
legend, CA) was applied corresponding to the mice sera, and goat
anti-human IgG (HþL)-FITC (1:50; SouthernBiotech, AL) was
applied corresponding to hMAb 6.4 C. After an incubation of
40 min at 37 °C, cells were washed in PBS, and observed for FITC
under a ﬂuorescence microscope (Nikon eclipse TE2000-5). All
ﬂuorescent pictures were taken with 20x objective lens.
Statistical analyses
The data were presented as the mean7the standard deviation.
Statistical analyses were performed with the nonpaired two-tailed
Student t-test, assuming unequal variance. Statistical signiﬁcance
was deﬁned as pr0.05.Competing interests
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